GSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, ...
Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a ...
Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, ...
Boehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with ...
Kos Biotechnology Partners has raised US$123m (€106m) for its inaugural global life sciences fund, marking a notable step for Greece’s still young biotechnology financing ecosystem. The New York- and ...
In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a ...
Qure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical ...
Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether ...
The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: ...
Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on ...
AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab ...
Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results